Scholarlink

Objective <p>To investigate the effectiveness of Xuanshen Yishen Decoction (XYD) in the treatment of hypertension.</p> Methods <p>Hospital electronic medical records from 2019–2023 were utilized to emulate a randomized pragmatic clinical trial. Hypertensive participants were eligible if they were aged ⩾40 years with baseline systolic blood pressure (BP) ⩾140 mm Hg. Patients treated with XYD plus antihypertensive regimen were assigned to the treatment group, whereas those who followed only antihypertensive regimen were assigned to the control group. The primary outcome assessed was the attainment rate of intensive BP control at discharge, with the secondary outcome focusing on the 6-month all-cause readmission rate.</p> Results <p>The study included 3,302 patients, comprising 2,943 individuals in the control group and 359 in the treatment group. Compared with the control group, a higher proportion in the treatment group achieved the target BP for intensive BP control [8.09% <i>vs</i>. 17.5%; odds ratio (OR)=2.29, 95% confidence interval (CI)=1.68 to 3.13; <i>P</i>&lt;0.001], particularly in individuals with high homocysteine levels (OR=3.13; 95% CI=1.72 to 5.71; <i>P</i>&lt;0.001; <i>P</i> for interaction=0.041). Furthermore, the 6-month all-cause readmission rate in the treatment group was lower than in the control group (hazard ratio=0.58; 95% CI=0.36 to 0.91; <i>P</i>=0.019), and the robustness of the results was confirmed by sensitivity analyse.</p> Conclusions <p>XYD could be a complementary therapy for intensive BP control. Our study offers real-world evidence and guides the choice of complementary and alternative therapies. (Registration No. ChiCTR2400086589)</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of Xuanshen Yishen Decoction on Intensive Blood Pressure Control: Emulation of a Randomized Target Trial Using Real-World Data

  • 期刊论文

  • 发表日期：

    2025年5月15日

查看全文
  • Xiao-jie Wang,
  • Yuan-long Hu,
  • Jia-ming Huan,
  • Shi-bing Liang,
  • Lai-yun Xin,
  • Feng Jiang,
  • Zhen Hua,
  • Zhen-yuan Wang,
  • Ling-hui Kong,
  • Qi-biao Wu,
  • Yun-lun Li

摘要

Objective

To investigate the effectiveness of Xuanshen Yishen Decoction (XYD) in the treatment of hypertension.

Methods

Hospital electronic medical records from 2019–2023 were utilized to emulate a randomized pragmatic clinical trial. Hypertensive participants were eligible if they were aged ⩾40 years with baseline systolic blood pressure (BP) ⩾140 mm Hg. Patients treated with XYD plus antihypertensive regimen were assigned to the treatment group, whereas those who followed only antihypertensive regimen were assigned to the control group. The primary outcome assessed was the attainment rate of intensive BP control at discharge, with the secondary outcome focusing on the 6-month all-cause readmission rate.

Results

The study included 3,302 patients, comprising 2,943 individuals in the control group and 359 in the treatment group. Compared with the control group, a higher proportion in the treatment group achieved the target BP for intensive BP control [8.09% vs. 17.5%; odds ratio (OR)=2.29, 95% confidence interval (CI)=1.68 to 3.13; P<0.001], particularly in individuals with high homocysteine levels (OR=3.13; 95% CI=1.72 to 5.71; P<0.001; P for interaction=0.041). Furthermore, the 6-month all-cause readmission rate in the treatment group was lower than in the control group (hazard ratio=0.58; 95% CI=0.36 to 0.91; P=0.019), and the robustness of the results was confirmed by sensitivity analyse.

Conclusions

XYD could be a complementary therapy for intensive BP control. Our study offers real-world evidence and guides the choice of complementary and alternative therapies. (Registration No. ChiCTR2400086589)